Literature DB >> 2481640

Dissection of the human antibody response to the malaria antigen Pf155/RESA into epitope specific components.

H Perlmann1, P Perlmann, K Berzins, B Wåhlin, M Troye-Blomberg, M Hagstedt, I Andersson, B Högh, E Petersen, A Björkman.   

Abstract

The development of vaccines is presently receiving major attention in malaria research. As it is not possible to base malaria vaccines on the use of killed or attenuated organisms, the vaccines which are being developed are subunit vaccines in which the immunogens consist of defined parasite antigens or antigenic fragments. Since protective immunity to malaria involves both antibody-dependent and antibody-independent mechanisms, the immunogens in a subunit vaccine must have the capacity to induce relevant B- and T-cell responses in the majority of vaccinees. In turn, this requires good knowledge of these responses in humans who have acquired immunity through natural infection. In this paper we have summarized our recent work on the dissection into epitope-specific components of the human antibody response to the Plasmodium falciparum antigen Pf155/RESA, a recognized candidate for a vaccine against the asexual blood stages of this parasite. Epitope mapping of the antigen by means of short synthetic peptides led to the identification in several molecular regions of short amino acid sequences constituting linear and probably immunodominant B-cell epitopes. The antigenically most active region was located in the C-terminus of the molecule. This region, which consists of approximately 40 related, 4- or 8-amino acid long repeats, induced higher antibody concentrations in a larger number of malaria-immune donors than any of the other regions. A large fraction of these antibodies bound to short synthetic peptides representing the major repeat motifs of Pf155/RESA. Although these repeats are made up of closely related amino acid sequences, the antibody response to them was highly polyclonal, indicating the presence of several linear and probably also conformational epitopes which gave rise to a variety of cross-reacting as well as monospecific antibodies. Further analysis revealed that the levels of antibodies differing in specificity and/or avidity for different peptides varied independently of each other in individual donors. In an area (Liberia) where malaria transmission is holoendemic and perennial, these antibody profiles remained constant when individual donors were followed over several years. Since the C-terminal repeat region of Pf155/RESA is conserved in different P. falciparum strains, the results reflect differences in the genetic regulation of epitope-specific host responses rather than antigenic differences between infecting parasites. In donors living in an area with high but seasonal malaria transmission, antibody levels usually drop to lower levels when there is no transmission.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2481640     DOI: 10.1111/j.1600-065x.1989.tb00555.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  30 in total

1.  Isolation of peptides that mimic epitopes on a malarial antigen from random peptide libraries displayed on phage.

Authors:  C G Adda; L Tilley; R F Anders; M Foley
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

2.  Structural and antigenic properties of merozoite surface protein 4 of Plasmodium falciparum.

Authors:  L Wang; C G Black; V M Marshall; R L Coppel
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

3.  Production by activated human T cells of interleukin 4 but not interferon-gamma is associated with elevated levels of serum antibodies to activating malaria antigens.

Authors:  M Troye-Blomberg; E M Riley; L Kabilan; M Holmberg; H Perlmann; U Andersson; C H Heusser; P Perlmann
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

4.  Isolation and serological characterization of a Plasmodium vivax recombinant antigen.

Authors:  Y D Sharma; V P Sharma; P Ray; S Laal; S D Sawant; S Verma
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

5.  A malaria serological map indicating the intersection between parasite antigenic diversity and host antibody repertoires.

Authors:  H A Giha; A A Nasr; N C Iriemenam; K Berzins; M Troye-Blomberg; D E Arnot; G Elghazali
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-06-29       Impact factor: 3.267

6.  Genetic regulation of human anti-malarial antibodies in twins.

Authors:  K Sjöberg; J P Lepers; L Raharimalala; A Larsson; O Olerup; N T Marbiah; M Troye-Blomberg; P Perlmann
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

7.  Cellular and humoral immune responses to well-defined blood stage antigens (major merozoite surface antigen) of Plasmodium falciparum in adults from an Indian zone where malaria is endemic.

Authors:  L Kabilan; V P Sharma; P Kaur; S K Ghosh; R S Yadav; V S Chauhan
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

8.  Seroreactivity with the Plasmodium falciparum blood stage antigen Pf332 in adults and children from malaria-endemic regions.

Authors:  J Iqbal; P Perlmann; B M Greenwood; K Berzins
Journal:  Clin Exp Immunol       Date:  1993-10       Impact factor: 4.330

9.  Antigen-specific influence of GM/KM allotypes on IgG isotypes and association of GM allotypes with susceptibility to Plasmodium falciparum malaria.

Authors:  Hayder A Giha; Amre Nasr; Nnaemeka C Iriemenam; David Arnot; Marita Troye-Blomberg; Thor G Theander; Klavs Berzins; Gehad ElGhazali; Janardan P Pandey
Journal:  Malar J       Date:  2009-12-22       Impact factor: 2.979

10.  FcgammaRIIa (CD32) polymorphism and anti-malarial IgG subclass pattern among Fulani and sympatric ethnic groups living in eastern Sudan.

Authors:  Amre Nasr; Nnaemeka C Iriemenam; Hayder A Giha; Halima A Balogun; Robin F Anders; Marita Troye-Blomberg; Gehad ElGhazali; Klavs Berzins
Journal:  Malar J       Date:  2009-03-13       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.